Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

Stopped early · Phase 2

Conditions studied: Pancreas, Adenocarcinoma

In brief

This is a multicenter, open label, randomized, phase 2b study, designed to evaluate the safety and efficacy of patients with locally advanced pancreatic adenocarcinoma following intratumoral administration of BC-819 and intravenously administered gemcitabine. Intratumoral injections of BC-819 will be performed using endoscopic ultrasound (EUS). Primary Objective: To assess the effect of intratumoral endoscopic ultrasound injection of BC-819 administered with intravenous gemcitabine on progression-free survival. Secondary Objectives: To compare the effects of intratumoral injection of BC-819 administered in combination with intravenous gemcitabine vs. intravenous gemcitabine alone on: Overall survival, Response rate, Resectability of the target tumor lesion, Quality of life, Safety, Serological Tumor Marker: CA 19-9, Duration of response, Failure-free survival

Key facts

Study ID

NCT01413087

Run by

Anchiano Therapeutics Israel Ltd.

People needed

12

Starts

2011-09-01

Expected to finish

2014-05-01

Last updated by the study team

2019-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females > 18 years of age
• If female, must not be pregnant or nursing; women of child-bearing potential must practice a medically approved method of contraception
• If male, must practice a medically approved method of contraception if have a partner of childbearing potential
• Histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas
• Locally advanced pancreatic cancer (LAPC) that is clinically unresectable as defined in the NCCN Guidelines
• Karnofsky performance status (KPS) ≥ 70% at baseline
• Adequate hematological, renal, and hepatic function
• Platelet count ≥ 100,000/mm3
• Absolute neutrophil count (ANC) ≥ 1500/mm3
• Hemoglobin ≥ 10.0 g/dL (may be achieved by transfusion)
• Creatinine (≤ 1.5 x ULN)
• ALT, AST (≤ 1.5 x ULN)
• Total Bilirubin (≤ 1.5 x ULN)
• Have a target tumor lesion in the pancreas ≤ 6 cm in diameter that is accessible for intratumoral administration by EUS guidance as determined by the physician performing the EUS injection
• Have a biopsy specimen that is positive for H19 expression (grade 2 or greater staining determined by a pathologist). H19 expression can be determined based on a biopsy specimen collected before study participation, if available.
• No prior diagnosis of malignancy within 3 years except for curatively treated non-melanoma skin or in situ malignancies
• Able to comply with the protocol procedures
• Able and willing to provide written (signed) Informed Consent to participate in the study

You may not qualify if…

• Have distant metastatic spread (such as liver or lung metastases), peritoneal spread or malignant ascites. Regional lymph node involvement may be considered in accordance with the PI's judgment
• Received any prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational, other than up to4 single doses of gemcitabine chemotherapy.Patients who received prior gemcitabine will only be eligible, if they enter the study without evidence of disease progression.
• Known human immunodeficiency virus (HIV) or hepatitis C virus (HCV) or hepatitis B virus (HBV) infection
• Have clinically significant pancreatitis within 12 weeks of treatment
• Have a clinical history of significant coagulopathy
• Have a medical condition contraindicated for endoscopic-guided delivery and/or for IV administration of Gemcitabine or any intercurrent medical illness or other medical condition that would in the judgment of the investigator compromise patient safety or the objectives of the study
• Have participated in any experimental therapeutic research study with an unapproved drug within 4 weeks of the screening visit
• Patients who require ongoing anticoagulation for pre-existing conditions, e.g., thrombophlebitis, pulmonary embolus or atrial fibrillation

Where it is running

• Winthrop University Hospital — Mineola, New York, United States
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States
• Joe Arrington Cancer Research & Treatment Center — Lubbock, Texas, United States
• Carmel Medical Center — Haifa, Israel
• Rambam Medical Center — Haifa, Israel
• Hadassah Medical Organization — Jerusalem, Israel
• Meir Medical Center — Kfar Saba, Israel
• Galil Maaravi — Nahariya, Israel
• Tel Aviv Medical Center — Tel Aviv, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.